Clinical Topics

Better Survival for NSCLC Patients Treated by Military Medicine

by U.S. Medicine

November 29, 2018

BETHESDA, MD—Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

That was the question examined in a new study published in Cancer Epidemiology, Biomarkers & Prevention. Survival of NSCLC patients treated within the MHS was compared to the U.S. general population.1

The study was led by researchers from the John P. Murtha Cancer Center, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center. MHS data for the study were from the DoD’s Automated Central Tumor Registry (ACTUR), while data for the general population came from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

The focus was on NSCLC patients diagnosed between Jan. 1, 1987, and Dec. 31, 2012, in ACTUR and a sample of SEER patients who were matched to the ACTUR patients on age group, sex, race and year of diagnosis group with a matching ratio of 1:4. Follow-up continued through Dec. 31, 2013.

Ultimately, 16,257 NSCLC patients were identified from ACTUR ,and 65,028 matched patients from SEER.

Results indicated that, Compared with SEER patients, ACTUR patients had significantly better overall survival (log-rank P < 0.001). The better overall survival among the ACTUR patients remained after adjustment for potential confounders (HR = 0.78, 95% confidence interval, 0.76-0.81).

Researchers emphasized that the survival advantage of the ACTUR patients was present regardless of cancer stage, grade, age group, sex or race.

“The MHS’s universal care and lung cancer care programs may have translated into improved survival among NSCLC patients,” study authors concluded, pointing out that their results confirms that NSCLC patients with universal care access have better outcomes.

1. Lin J, Kamamia C, Brown D, Shao S, McGlynn KA, Nations JA, Carter CA, Shriver CD, Zhu K. Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER Population. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):673-679. doi: 10.1158/1055-9965.EPI-17-0822.

Related Articles

Increasing Usage of SSRIs for Dementia Symptoms

Emerging data has suggested effectiveness for selective serotonin reuptake inhibitors for treatment of behavioral and psychological symptoms of dementia.

PhARMD Program Continues to Expand Pharmacists’ Clinical Role in VA

A tool developed by the VA has raised the profile of pharmacists as critical members of patient care teams at the VA, leading to a doubling of the number of pharmacists serving as providers.

U.S. Medicine Recommends

More From oncology


Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.


VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.


VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.


Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.


Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up